Skip to main content
TipRanks
Go Ultimate75% OFF

Boundless Bio Inc. (BOLD) Drug Pipeline

54 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Fulvestrant, Bbi-940Advanced Breast Cancer, Breast Cancer, Metastatic Breast CancerPhase INot Yet RecruitingStudy of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast CancerJan 22, 2026―
Bbi-825Solid TumorPhase ITerminatedStudy of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene AmplificationsFeb 26, 2024
Erlotinib, Bbi-825, Bbi-355, FutibatinibSmall Cell Lung Cancer, Pancreatic Cancer Metastatic, Triple Negative Breast Cancer (Tnbc), Er+ Breast Cancer, Cervical Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma (Cscc), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma, Anogenital Cancer, Head And Neck (Hnscc), Leiomyosarcoma (Lms), Undifferentiated Pleomorphic Sarcoma (Ups)Phase IActive Not RecruitingStudy of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene AmplificationsMar 27, 2023

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Boundless Bio Inc. (BOLD) have in its pipeline
Boundless Bio Inc. BOLD is currently developing the following drugs: Fulvestrant, Bbi-940, Bbi-825, Erlotinib, Bbi-825, Bbi-355, Futibatinib. These drug candidates are in various stages of clinical development as the company works toward FDA approval.